The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Pharmacological Treatment of Atrial Fibrillation

심방세동의 약물치료

  • Oh, Se-Il (Department of Internal Medicine, Seoul National University College of Medicine)
  • 오세일 (서울대학교 의과대학 내과학교실)
  • Published : 2011.10.01
⟨ Previous Next ⟩

Abstract

Atrial fibrillation is the most common and most complex sustained arrhythmia. However, its pathophysiology has not been completely elucidated, therefore various approaches have been applied to its therapeutics. The management including pharmacological treatment is still evolving, and guidelines of atrial fibrillation have been updated frequently. This review article will introduce the principles and practical information on the pharmacological management in patients with atrial fibrillation based on the recently updated guidelines.

Keywords

References

  1. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429. https://doi.org/10.1093/eurheartj/ehq278
  2. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011;123:e269-e367. https://doi.org/10.1161/CIR.0b013e318214876d
  3. Gillis AM, Verma A, Talajic M, Nattel S, Dorian P. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. Can J Cardiol 2011;27:47-59. https://doi.org/10.1016/j.cjca.2010.11.001
  4. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-1373. https://doi.org/10.1056/NEJMoa1001337
  5. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-678. https://doi.org/10.1056/NEJMoa0803778
  6. FDA Drug Safety Communication: Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events [Internet]. [cited 2011 Aug 2]. Available from: http://www.Fda.Gov/drugs/drugsafety/ucm264059.Htm.